Registry following people with COPD who take dupilumab in everyday care
Follows adults with COPD treated with dupilumab, and compares them with others.
Plain-language title generated from the registry record
Registry title: The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
Key facts
- Where
- Columbus, Durham, Houston, Indianapolis, Kingwood, Lawrence, and North Richland Hills, United StatesSee the 7 sites
Where in United States
- Ohio State UniversityColumbus, United StatesTaking people
- DukeDurham, United StatesTaking people
- The Respire InstituteHouston, United StatesTaking people
- IU Health Pulmonology & Critical Care MedicineIndianapolis, United StatesTaking people
- Activian Clinical ResearchKingwood, United StatesTaking people
- University of KansasLawrence, United StatesTaking people
- The Lung & Sleep Institute of North TexasNorth Richland Hills, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sanofi
- Trial code
- NCT07612878
- Record updated
- 15 October 2026
- Original description
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.Read full original descriptionShow less
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.
Inclusion: COPD patients who are newly referred to start dupilumab treatment; Age ≥ 40 years; Standard of care spirometry performed concurrently with the baseline visit or within 90 days prior to the baseline visit.
Exclusion: Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments; Patients who have contraindication to dupilumab according to the United States Prescribing Information (USPI); Patients currently participating in any interventional clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.